Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880320 · ClinicalTrials.gov registry record · Phase 3
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 503
- Enrollment target
NCT01880320 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 503 participants.
The verdict
NCT01880320, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 503 participants
- Enrollment target
Study Summary
The study hypothesis are based on the assumption that : * CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects * CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable safety and tolerability profile
Interventions
- DRUG Topical Gel Vehicle
- DRUG CD0271 0.3% / CD1579 2.5%
- DRUG CD0271 0.1% / CD1579 2.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880320
The ClinicalTrials.gov registry entry for NCT01880320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Topical Gel Vehicle is the first listed.
NCT01880320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880320 about?
NCT01880320 is a clinical study titled "Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris". The study hypothesis are based on the assumption that : * CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects * CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acc...
What is the current status of trial NCT01880320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 503 participants. The study started on 2013-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01880320?
The interventions under investigation include: Topical Gel Vehicle (DRUG), CD0271 0.3% / CD1579 2.5% (DRUG), CD0271 0.1% / CD1579 2.5% (DRUG).
Who is sponsoring clinical trial NCT01880320?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.